AR065698A1 - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
AR065698A1
AR065698A1 ARP080101006A ARP080101006A AR065698A1 AR 065698 A1 AR065698 A1 AR 065698A1 AR P080101006 A ARP080101006 A AR P080101006A AR P080101006 A ARP080101006 A AR P080101006A AR 065698 A1 AR065698 A1 AR 065698A1
Authority
AR
Argentina
Prior art keywords
solid preparation
compound
microcrystalline cellulose
salts
methyl
Prior art date
Application number
ARP080101006A
Other languages
English (en)
Inventor
Miyuki Hohokabe
Yusuke Murakawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR065698A1 publication Critical patent/AR065698A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Una preparacion solida que contiene 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2H)-pirimidinil]metil]-4-fluorobenzonitrilo (compuesto (A)) o una de sus sales como ingrediente farmacéuticamente activo. Específicamente, una preparacion solida que contiene un gránulo formado por el compuesto (A) o una de sus sales y un aditivo (excluyendo la celulosa microcristalina) y un comprimido que contiene (a) un gránulo que contiene el compuesto (A) o una de sus sales y celulosa microcristalina, y (b) una ayuda para formar comprimidos que contiene estearato de magnesio y celulosa microcristalina.
ARP080101006A 2007-03-13 2008-03-12 Preparacion solida AR065698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007064245 2007-03-13

Publications (1)

Publication Number Publication Date
AR065698A1 true AR065698A1 (es) 2009-06-24

Family

ID=39409986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101006A AR065698A1 (es) 2007-03-13 2008-03-12 Preparacion solida

Country Status (10)

Country Link
US (1) US7994183B2 (es)
EP (1) EP2120885A2 (es)
JP (1) JP5432720B2 (es)
AR (1) AR065698A1 (es)
CA (1) CA2680684A1 (es)
CL (1) CL2008000727A1 (es)
MX (1) MX2009009703A (es)
PE (1) PE20090015A1 (es)
TW (1) TW200900094A (es)
WO (1) WO2008114800A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN103816158A (zh) 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
CN106177958A (zh) 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
AU2010279171A1 (en) * 2009-07-28 2012-03-01 Takeda Pharmaceutical Company Limited Tablet
NZ625577A (en) 2009-10-02 2015-12-24 Boehringer Ingelheim Int Therapeutic uses of pharmaceutical compositions
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013179307A2 (en) * 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
UY34847A (es) * 2012-06-05 2014-01-31 Takeda Pharmaceutical Preparacion sólida
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
MX2016017315A (es) * 2014-07-07 2017-04-27 Novartis Ag Formas de dosificacion farmaceutica.
CN104825413B (zh) * 2015-05-25 2019-12-20 浙江华海药业股份有限公司 一种含有琥珀酸曲格列汀的口服片剂及其制备方法
CA2987850A1 (en) * 2015-06-17 2016-12-22 Hexal Aktiengesellschaft Alogliptin formulation
CN105596341B (zh) * 2016-03-14 2018-08-10 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
EP4189016B1 (en) 2021-04-01 2024-02-14 Sun Chemical Corporation Aqueous inkjet compositions comprising hydroxy-functional polyurethane dispersions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
NZ230763A (en) * 1988-09-27 1991-10-25 Takeda Chemical Industries Ltd Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
JP3004758B2 (ja) * 1991-04-17 2000-01-31 旭化成工業株式会社 結合性、崩壊性に優れる加工澱粉
PL220457B1 (pl) * 2002-12-16 2015-10-30 Kissei Pharmaceutical Kapsułka do leczenia dysurii
WO2005067976A2 (en) 2004-01-20 2005-07-28 Novartis Ag Direct compression formulation and process
AU2005210004B2 (en) * 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
CN102134231B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EA015169B1 (ru) 2005-09-14 2011-06-30 Такеда Фармасьютикал Компани Лимитед Применение ингибиторов дипептидилпептидазы
ATE522216T1 (de) 2006-09-13 2011-09-15 Takeda Pharmaceutical Verwendung von 2-6-(3-amin-piperidin-1-yl)-3- methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1- ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv- infektionen
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8697125B2 (en) * 2007-02-01 2014-04-15 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
PE20090987A1 (es) * 2007-08-16 2009-08-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido

Also Published As

Publication number Publication date
JP5432720B2 (ja) 2014-03-05
US7994183B2 (en) 2011-08-09
MX2009009703A (es) 2010-03-03
CL2008000727A1 (es) 2008-10-17
JP2010521416A (ja) 2010-06-24
WO2008114800A8 (en) 2009-04-09
WO2008114800A2 (en) 2008-09-25
CA2680684A1 (en) 2008-09-25
PE20090015A1 (es) 2009-01-30
TW200900094A (en) 2009-01-01
US20100105710A1 (en) 2010-04-29
WO2008114800A3 (en) 2008-12-24
EP2120885A2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
AR065698A1 (es) Preparacion solida
CR9875A (es) Inhibidores de dipeptidilo peptidasa para tratar diabetes
PE20140923A1 (es) Preparacion solida que comprende alogliptina y clorhidrato de metformina
RS54492B1 (en) KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
GEP20125410B (en) Solid preparation comprising alogliptin and pioglitazone
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
UA112298C2 (uk) Бензімідазолові інгібітори респіраторно-синцитіального вірусу
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
ECSP12011645A (es) Compuestos y métodos inhibidores de jak de pirazolopirimidina
MX2011010332A (es) Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
EA201270216A1 (ru) Фармацевтический состав
CR20120061A (es) Tableta
MY155938A (en) Oral pharmaceutical composition
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
ES2527194T3 (es) Derivados de tetrahidroquinolina utilizados como activadores de AMPK
AR092843A1 (es) Preparacion solida
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
TH102392B (th) การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส
TH102393A (th) การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส
EA200901151A1 (ru) Способ получения золмитриптана
TH102393B (th) การดำเนินการให้ของสารยับยั้งไดเปปติดิล เปปติเดส

Legal Events

Date Code Title Description
FB Suspension of granting procedure